Breast Cancer Liquid Biopsy Testing Devices Market by Offerings (Assay & Reagents Kits, Instruments), Circulating Biomarker (Circulating Tumar DNA, Circulating Tumor Cell, Extracellular Vesicles), End-User, Appplication - Global Forecast 2024-2030

Breast Cancer Liquid Biopsy Testing Devices Market by Offerings (Assay & Reagents Kits, Instruments), Circulating Biomarker (Circulating Tumar DNA, Circulating Tumor Cell, Extracellular Vesicles), End-User, Appplication - Global Forecast 2024-2030


The Breast Cancer Liquid Biopsy Testing Devices Market size was estimated at USD 858.76 million in 2023 and expected to reach USD 1,023.60 million in 2024, at a CAGR 19.59% to reach USD 3,004.57 million by 2030.

Global Breast Cancer Liquid Biopsy Testing Devices Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Breast Cancer Liquid Biopsy Testing Devices Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Breast Cancer Liquid Biopsy Testing Devices Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Liquid Biopsy Testing Devices Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Inc., BioVIew Ltd., Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health, Inc., Illumina, Inc., Isogen Life Science B.V., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., Menarini Group, Merck KGaA, Myriad Genetics, Inc., Natera Inc., Neogenomics Laboratories, Inc., OncoDNA SA, Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage



This research report categorizes the Breast Cancer Liquid Biopsy Testing Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

Offerings
Assay & Reagents Kits
Instruments
Circulating Biomarker
Circulating Tumar DNA
Circulating Tumor Cell
Extracellular Vesicles
End-User
Hospitals
Research Laboratories
Appplication
Diagnosis
Monitoring
Screening/Early Detection
Treatment Selection
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Breast Cancer Liquid Biopsy Testing Devices Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Breast Cancer Liquid Biopsy Testing Devices Market?
3. What are the technology trends and regulatory frameworks in the Breast Cancer Liquid Biopsy Testing Devices Market?
4. What is the market share of the leading vendors in the Breast Cancer Liquid Biopsy Testing Devices Market?
5. Which modes and strategic moves are suitable for entering the Breast Cancer Liquid Biopsy Testing Devices Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Breast Cancer Liquid Biopsy Testing Devices Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of breast cancer among women worldwide
5.1.1.2. Increasing demand for non-invasive breast cancer treatment
5.1.1.3. Surge in pre-screening programs for breast cancer detection
5.1.2. Restraints
5.1.2.1. Concerns related to the accuracy of testing devices
5.1.3. Opportunities
5.1.3.1. Technological advancements in breast cancer liquid biopsy testing devices
5.1.3.2. Investments in R&D for breast cancer testing
5.1.4. Challenges
5.1.4.1. Presence of strict standards for liquid biopsy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Breast Cancer Liquid Biopsy Testing Devices Market, by Offerings
6.1. Introduction
6.2. Assay & Reagents Kits
6.3. Instruments
7. Breast Cancer Liquid Biopsy Testing Devices Market, by Circulating Biomarker
7.1. Introduction
7.2. Circulating Tumar DNA
7.3. Circulating Tumor Cell
7.4. Extracellular Vesicles
8. Breast Cancer Liquid Biopsy Testing Devices Market, by End-User
8.1. Introduction
8.2. Hospitals
8.3. Research Laboratories
9. Breast Cancer Liquid Biopsy Testing Devices Market, by Appplication
9.1. Introduction
9.2. Diagnosis
9.3. Monitoring
9.4. Screening/Early Detection
9.5. Treatment Selection
10. Americas Breast Cancer Liquid Biopsy Testing Devices Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Breast Cancer Liquid Biopsy Testing Devices Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Testing Devices Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Agilent Technologies, Inc.
14.1.2. Becton, Dickinson and Company
14.1.3. Bio-Rad Laboratories, Inc.
14.1.4. Biocept, Inc.
14.1.5. Biodesix, Inc.
14.1.6. BioVIew Ltd.
14.1.7. Eurofins Scientific SE
14.1.8. Exact Sciences Corporation
14.1.9. F. Hoffmann-La Roche AG
14.1.10. Fluxion Biosciences Inc.
14.1.11. Guardant Health, Inc.
14.1.12. Illumina, Inc.
14.1.13. Isogen Life Science B.V.
14.1.14. Johnson & Johnson Services, Inc.
14.1.15. Laboratory Corporation of America Holdings
14.1.16. Lucence Health Inc.
14.1.17. Menarini Group
14.1.18. Merck KGaA
14.1.19. Myriad Genetics, Inc.
14.1.20. Natera Inc.
14.1.21. Neogenomics Laboratories, Inc.
14.1.22. OncoDNA SA
14.1.23. Qiagen N.V.
14.1.24. Sysmex Corporation
14.1.25. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET RESEARCH PROCESS
FIGURE 2. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2023 VS 2030
FIGURE 3. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET DYNAMICS
FIGURE 7. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2023 VS 2030 (%)
FIGURE 8. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2023 VS 2030 (%)
FIGURE 10. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2023 VS 2030 (%)
FIGURE 14. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings